<DOC>
	<DOC>NCT01929707</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of two dosing periods. At least seven days will pass between doses. This study will last approximately 45 days for each participant. Screening is required within 28 days before the start of the study.</brief_summary>
	<brief_title>A Study of LY3050258 in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy males or healthy postmenopausal females, including Japanese participants Have a body mass index of 18 to 35 kilograms per square meter (kg/m^2) An abnormal sitting blood pressure as determined by the investigator Any abnormality in the 12lead electrocardiogram that, in the opinion of the investigator, places the participant at an unacceptable risk for study participation Current use of statins within the last 3 months prior to dosing Current use or previous use of anabolic steroids in the preceding 6 months prior to dosing Use of dehydroepiandrosterone, other potential overthecounter (OTC) steroidal supplements, or other nutritional products intended to have weightreduction and/or performanceenhancing effects within 21 days prior to dosing</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>